Vaxart Inc (Vaxart) is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary Vector-Adjuvant-Antigen Standardized Technology (VAAST) platform. The company primarily targets infectious diseases such as norovirus, coronavirus (including SARS-CoV-2), and influenza. Additionally, Vaxart is working on a therapeutic vaccine candidate for cervical cancer and dysplasia caused by human papillomavirus (HPV).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Vaxart is engaged in several R&D initiatives, focusing on developing oral recombinant vaccines using its proprietary VAAST platform. The company's efforts are directed towards creating vaccines for infectious diseases such as norovirus, coronavirus (including SARS-CoV-2), and influenza, as well as a therapeutic vaccine candidate for cervical cancer and dysplasia caused by HPV. Their main efforts include the development of COVID-19 vaccine candidates targeting the SARS-CoV-2 XBB and KP.2 strains, a second-generation norovirus vaccine candidate, and a trivalent seasonal influenza vaccine candidate. The VAAST platform is designed to generate both systemic and mucosal immunity and employs a vector-based approach using non-replicating adenovirus type 5 (Ad5) to deliver DNA coding for vaccine antigens and an adjuvant to the small intestine. The platform's thermostable oral pill format has the potential to revolutionize vaccine distribution and administration. In FY2025, the company incurred expenses of US$201.6 million on R&D, which as a percentage of revenue, stood at 85%.